Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... in many countries for the treatment of AML with 20%-30% blasts and multilineage dysplasia according to the World Health ... of azacitidine treatment of patients with AML with >30% blasts have also been shown in a recent phase III trial. Oral administration of ...

    Research Article last updated 12/09/2015 - 8:49am.

  2. Myelodysplastic syndromes: Contemporary review and how we treat

    ... peripheral blood and bone marrow dysplasia/ blasts , and clonal cytogenetic abnormalities. With the advent of next ...

    Research Article last updated 04/29/2016 - 1:05pm.

  3. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

    ... acute myeloid leukemia with 20-30% bone marrow blasts . Patients were treated with azacitidine, with one of three dosage ...

    Research Article last updated 05/22/2014 - 9:28am.

  4. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... analysis of peripheral cytopenias, percentage of blasts in the bone marrow and cytogenetic characteristics. The most ... based on risk, transfusion needs, percent of bone marrow blasts and more recently cytogenetic profile. Goals of therapy are different ...

    Research Article last updated 02/04/2014 - 1:37pm.

  5. Expression of DLK1 Gene in the Bone Marrow Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significance.

    ... positive correlation with the proportion of bone marrow blasts (r=0.467, P<0.05). Moreover, DLK1 mRNA expression was significantly ... positively correlated with the proportion of the bone marrow blasts. A high expression of DLK1 gene suggested a higher malignant clone ...

    Research Article last updated 06/20/2013 - 10:42am.

  6. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... include analysis of peripheral cytopenias, percentage of blasts in the bone marrow and cytogenetic characteristics. The most ... based on risk, transfusion needs, percent of bone marrow blasts, and, more recently, cytogenetic profile. Goals of therapy are different ...

    Research Article last updated 07/31/2012 - 2:02pm.

  7. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... include analysis of peripheral cytopenias, percentage of blasts in the bone marrow, and cytogenetic characteristics. The most ... based on risk, transfusion needs, percent of bone marrow blasts and more recently cytogenetic profile. Goals of therapy are different in ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Clinical effect of point mutations in myelodysplastic syndromes

    ... including specific cytopenias, the proportion of blasts , and overall survival. RESULTS: We identified somatic ... all comparisons) and an increased proportion of bone marrow blasts (P<0.006 for all comparisons). In a multivariable Cox regression model, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.

    ... to pre-defined criteria ( cellularity <20% and blasts <10%). Marrow cellularity (P<0.0001) and blast% (P=0.03) were ... with inferior OS after HCT (HR=1.22 for each 10% marrow blasts, 95% CI: 1.02-1.46). For AML/MDS patients, there was a suggestion that ...

    Research Article last updated 06/28/2013 - 1:30pm.

  10. Current and novel therapeutic approaches in myelodysplastic syndromes

    ... remissions, and reduction in bone marrow blasts . 5-azacitidine has also been shown to improve overall survival. ...

    Research Article last updated 05/26/2015 - 12:13pm.